Download the slides

---

Related articles :

• PIVOT
• MOBIDIP

---

Table of contents

Switch to PI/r monotherapy
MOBIDIP Study
Original article : Ciaffi L, Lancet HIV 2017; 4:e384-92
Last update : 28/09/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

• After viral suppression with a second-line cART of PI/r plus 2 NRTIs, maintenance with PI/r plus 3TC is associated with
  • A higher rate of success than PI/r monotherapy despite the presence of M184V mutation
    • Significant more virological failures with PI/r (24.8% vs 3.0%)
  • A similar CD4 response and adherence
  • No differences in safety outcomes

Design

Objective

• Primary endpoint: failure rate at W96 by ITT, defined as 1) a confirmed HIV RNA > 500 c/mL, 2) reintroduction of the NRTI backbone or 3) interruption of the PI
• March 2016: Monotherapy arm discontinued following DSMB meeting

Baseline characteristics and primary outcome at W48

* All failures resuppressed to HIV RNA < 200 c/mL a median of 10 weeks after NRTI reintroduction

Other results

• Failure not associated with
  • Adherence
  • Nadir CD4 count
  • PI
• CD4 gain similar in both groups at W48
• No differences in safety (PI/r monotherapy vs PI/r + 3TC)
  • Severe adverse events = 11% (13% vs 10%)
  • AIDS-defining events = 3% (5% vs 2%)
  • No treatment interruptions for intolerance
  • Laboratory parameters : no differences
    • Changes in eGFR similar
    • Minimal changes in lipid parameters

Follow-up of dual therapy (PI/r + 3TC) arm at W96, N = 132

• Confirmed virological failure (2 consecutive HIV RNA > 500 c/mL)
  • N = 8 (virological success = 94% [ HIV RNA < 50 c/mL: 79%])
  • Genotype testing in 7/8: 2 lost M184V mutation, none developed PI or new NRTI mutations
  • Reintroduction of TDF in 5/8 participants: 4/5 resuppressed, 1 data missing
  • No change in 3 participants: resuppressed without change
• 3 discontinuations for non virological failure
• Global treatment success rate at W96: 91.7%

Back to Table of Contents